Comparative Pharmacology
Head-to-head clinical analysis: DOXAZOSIN MESYLATE versus MINIPRESS XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXAZOSIN MESYLATE versus MINIPRESS XL.
DOXAZOSIN MESYLATE vs MINIPRESS XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min)
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%)
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker